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Introduction
Fungal infections are commonly neglected during differential 
diagnosis on clinical care. However, they should be considered in 
all patients with chronic sinusitis because they affect significant 
numbers of patients. Fungal infections of the sinuses have 
recently been attributed to most cases of chronic rhinosinusitis, 
although supporting evidence is still controversial. Most fungal 
sinus infections are benign or noninvasive, except when they 
occur in individuals who are immunocompromised [20, 21]. 
Invasive fungal infections in immunocompetent individuals do 
occur [1] and this subset of patients should not be overlooked. 
A review of the literature and presentation of 4 clinical cases 
of fungal rhinosinusitis (FRS) are presented in this article.
4 Case Reports
Case 1 – Scopulariopsis 
A 54-year-old male smoker with a history of multiple traumatic 
events to the nose presented to the clinic with chronic facial pain 
with pressure and a series of 6 acute sinus exacerbations occurring 
over 11 months, requiring antibiotic therapy. The patient claimed 
right-sided facial pain/pressure and foul-smelling yellow 
discharge along with fever and chills. He also reported chronic 
itchy, watery eyes and intermittent rhinorrhea and current 
treatment with nasal steroid spray, saline nasal irrigation, 
and a decongestant. His rhinological exam demonstrated no 
external ecchymosis, diffuse mild erythema of the midline 
septum, which deviated slightly to the right and an exudate 
within the middle meatus, bilaterally, with thick secretions. 
The mucosa showed no polypoid degeneration. Radiologically, 
CT of the sinuses showed extensive chronic sinusitis involving 
primarily the right maxillary sinus but also extending into the 
right side of the ethmoids and frontal sinus towards the right 
side which was completely opacified, suggesting inflammation. 
There was only minimal mucosal thickening of the floor of the 
left maxillary sinus. The medial wall of the right maxillary sinus 
was absent but demonstrated an amorphous high attenuation 
material that was suspicious for mycetoma. The right ethmoid 
conchae were markedly attenuated to absent. A soft tissue 
density was present that extended into the right frontal ethmoidal 
recess and slightly into the right side of the frontal sinus. Bilateral 
endoscopic ethmoidectomy was performed with removal of the 
right maxillary sinus contents which were sent to pathology. The 
patient’s complete blood count was normal. Pathology revealed 
benign respiratory epithelium covered mucosa with marked 
acute and chronic nonspecific inflammation with focal erosion 
and numerous fungal microorganisms. A microbiologist consult 
revealed that the fungal morphology seen in the specimen was 
consistent with Scopulariopsis [2]. Numerous clusters of “door 
knob” shaped spiny conidia were evident (Fig. 1). Conidia were 
present singularly, and in chains, characteristic of this mold. 
Scopulariopsis species are keratinophilic and are most 
commonly associated with onychomycosis; however, more 
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Figure 1.  A.  Scopulariopsis sp. in sinus biopsy, 400X, GMS 
stain.  B.  Flat sided, door-knob shaped echinulate spores (arrow), 
1000X, Grocott’s methenamine silver (GMS) stain.  C-D Scopu-
lariopsis grown on Sabouraud dextrose agar (SABDX); C.  Colo-
ny at 5 days, incubated at 30°C.  D.  Lactophenol cotton blue stain 
(LPBC), 400X, showing chains of flat sided echinulate spores. 
recently there have been some reports of invasive infections. Of 
these, about 90% are associated with one of the following risk 
factors: AIDS, organ transplantation, corticosteroid therapy, 
peritoneal dialysis, surgery, cardiac disease, and trauma. 
Scopulariopsis is a large genus of saprophytic organisms found 
mostly in soil, but frequently isolated from food, paper, and 
other materials [3]. Within the genus are members of both 
hyalohyphomycoses and phaeohyphomycoses. Of the hyaline 
species, S. brevicaulis is responsible for causing most of human 
infections while S. candidum and S. acremonium have also been 
reported to cause disease in humans [4]. The organism has been 
reported as a cause of rhinosinusitis [2,4,5,6,7]. The pathological 
diagnosis of Scopulariopsis can be made from the characteristic 
conidial morphology since there are few fungi that resemble 
these microorganisms. However, the organism is highly 
cultivable and grows on various mycology media commonly 
found in the clinical laboratory. In this case, removal of the 
infected material was sufficient to resolve the infection without 
antifungal therapy. The patient improved and in a 2-year follow-
up, he was healthy without recurrence of symptoms or infection. 
 
Case 2 – Cunninghamella
A 67-year-old male smoker with a history of insulin dependent 
diabetes mellitus and hypertension, presented to evaluation at 
the ENT clinics for nasal congestion. His symptoms began 25 
years ago with right side nasal polyps requiring polypectomy 
at that time. He stated that recently the nasal congestion was 
worse to the point he could not use his CPAP machine. He was 
taking Fluticasone without any improvement. No facial pain or 
pressure was identified at physical examination. A CT of the 
sinus was performed with a descriptive polypoid soft tissue 
density involving the right nasal cavity adjacent to the midline 
turbinate, which was concerning for a nasal polyp. A significant 
soft tissue density involving the base of the left maxillary sinus 
with central hyper density including speckled calcified densities 
indicated that could represent fungal infection. After this finding 
he went to surgery and a bilateral anterior ethmoidectomy with 
right side polypectomy was performed. Pathology reported 
numerous of fungal hyphae morphologically consistent with 
Zygomycetes. A Microbiologist consult was obtained. The 
fungus was identified from the tissue sections as most consistent 
with Cunninghamella. The organism showed aseptate ribbon-
like hyphae, with a vesicle supporting multiple denticles giving 
rise to echinulate sporangiola (spores) (Fig. 2). 
Cunninghamella, is a saprobic fungus commonly found in the 
soil of temperate climates. It’s a rare cause of zygomycosis in 
humans often associated with trauma and immunosuppression. 
[8]. The genus Cunninghamella in the order of Mucorales 
encompasses filamentous fungi that are inhabitants of soil and 
other environments and are common laboratory contaminants. 
C. bertholletiae is the only member of the genus documented to 
cause human infections [9].
Case 3 – Blastomycosis
A 55-year-old male smoker with a history of diabetes mellitus 
and hypertension, presented with a right sided maxillary and 
ethmoid sinusitis and preseptal cellulitis. His symptoms began 
3 months prior, and consisted of right orbital pain and pressure, 
headache, with a white to yellow drainage from the right nares. 
A CT of the chest was performed which showed a right hilar 
mass. He had an elevated white cell count of 19,400/mm3. 
A transbronchial lung biopsy and endobronchial ultrasound 
biopsy were performed but both showed only inflammatory 
tissue. A bronchial brush specimen subsequently yielded 
negative microbiology cultures. Treatment with nasal rinses, 
corticosteroid spray, and antibiotics were at first helpful but 
soon, earlier symptoms returned. Two months later, the patient 
returned with progressive fevers, chills, night sweats, posterior 
headache, and weight loss with continued right sided facial 
pain and drainage from the right nares. He denied any neck 
stiffness and had no other complaints. The patient underwent 
two right nasal septum biopsies which were sent to pathology 
and microbiology. He was initially started on fluconazole until 
laboratory results from the biopsy were completed. The right 
nasal septum biopsy showed yeasts, present in respiratory 
mucosa with severe-acute, chronic, and granulomatous 
inflammation, with necrosis. A right lateral nasal vestibule 
lesion biopsy showed squamous epithelium-lined mucosa 
with severe acute, chronic, and granulomatous inflammation, 
ulceration, and epithelial marked hyperplasia. Pathology 
obtained a microbiologist consult which identified the yeast 
as broad base budding yeast cells 10-20 µm in diameter, with 
thickened cell wall, and the absence of hyphae or pseudohyphae, 
most consistent with Blastomyces dermatitidis (Fig. 3). 
Microbiology fungal and mycobacterial stains were all negative 
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Figure 2.  A.  Fungus ball in sinus biopsy, 100X, GMS stain.; B.  Cunninghamella showing ribbon like, aseptate, hyphae (arrows), 
1000X, GMS stain.; C. Columella and fruiting head of Cunninghamella, in sinus biopsy, 400X, GMS stain.; D.  Round, echinulate spores 
of Cunninghamella (arrows), 1000X, GMS stain.; E.  Typical fruiting head of Cunninghamella grown on SABDX, LPCB stain, 1000X.; F.  
Echinulate sporangiola, LPCB stain, 2000X. 
and cultures remained negative at five weeks. An infectious 
disease consult was immediately obtained, and the patient was 
started on itraconazole therapy for blastomycosis. Continued 
follow-up visits were scheduled along with CT of the head to rule 
out cerebral abscess. 
Blastomyces dermatitidis is another fungus unique to different 
geographical areas which may find a focal niche in the sinuses 
and cause chronic invasive fungal rhinosinusitus. The dimorphic 
fungus typically exists in the warm, moist soil of wooden areas 
ricing in organ debris. Regions of Wisconsin and Tennessee are 
highly endemic for blastomycosis [10]. Mostly, patients infected 
with B. dermatitidis develop asymptomatic illness. This fungus 
has the potential to affect bones. A three-decade survey of 
skeletal blastomycosis at a United States Medical Center 
revealed 31 cases; of those, 7(23%) showed skull and facial bone 
involvement [10]. 
Case 4 – A. fumigatus
A 53-year-old, immunocompetent, white male with a 35-year 
history of allergic rhinitis, sinusitis, and septoplasty performed 
26 years ago for a deviated septum, presented to the emergency 
department with increased nasal drainage over several weeks, 
and a feeling of sinus pressure and regular headaches on the 
right side, with no fevers but intermittent chills. He was given 
two weeks of amoxicillin-clavulanic acid along with a nasal 
decongestant and discharged. The patient returned twelve 
days later with continued symptoms of right-sinus pain and 
nasal discharge. A CT scan revealed complete opacification of 
the right maxillary sinus with a soft tissue mass extending in 
to the right side of the ethmoid air cells and towards the right 
frontoethmoidal recess. There were also findings to suggest 
changes of chronic right maxillary sinusitis with osteitis of 
the other walls of the right maxillary sinus. Endoscopic sinus 
surgery was performed and a biopsy of a suspected “fungal 
ball” from the right sinus was sent to microbiology for culture. 
Bacteriology recovered Escherichia coli, ampicillin resistant. 
Mycology recovered on the sixth day of incubation, a white-to-
light-green mold from which vesicles were produced from single, 
broad, conidiophores (lacking rounded vesicles) along septate 
hyphae (Fig. 4). MALDI-TOF was performed on the isolate by 
the method of De Carolis et. al. [11] using the Bruker Daltonics 
filamentous fungi library v.1.0, which yielded Aspergillus 
fumigatus, log scores of 2.09, 1.79, and 1.73. The mold grew on 
brain heart infusion -5% sheep blood agar at 30°C, and 45°C, but 
not at 55°C. Because microscopic morphology was inconsistent 
with Aspergillus, the isolate was referred to the University 
of Texas Health, San Antonio Department of Pathology and 
Laboratory Medicine, Fungus Testing Laboratory, San Antonio, 
Texas. Phenotypic characterization and DNA sequencing of the 
targets, ITS, D1/D2, TUB and CAL, identified the isolate as A. 
fumigatus. Their lab also reported susceptibility testing results 
of amphotericin B (MIC =0.5 µg/ml), fluconazole (MIC >64 µg/
ml), itraconazole (MIC =0.5 µg/ml), and isavuconazole (MIC 
=0.5 µg/ml) in accordance with CLSI M38-A2 document [12].
Due to this atypical morphology for A. fumigatus, the possibility 
that this isolate was its anamorph, Neosartorya, we reviewed 
the previously published morphological characteristics of 
Aspergillus section Fumigati and its teleomorph Neosartorya 
[13]. The closest matching microscopic morphological features 
were similar with A. unilateralis. Microscopically, our isolate 
failed to demonstrate the characteristic rounded “aspergilli 
vesicle” but instead showed a segmented conidiophore with 
a central elongated vesicle (Fig. 4, C-D) with a central 
enlarged phialide and secondary smaller phialides produced 
on metulae. We noted that single-opposing conidiophores were 
sometimes produced at right angles along the hyphae, similar 
with those shown in Fig. 4C. The colonial morphology of our 
isolate was dissimilar to A. unilateralis. The colony surface 
remained white for several days, developing only light mint 
green coloration toward the center of the colony whereas A. 
unilateralis is fully green. The reverse morphology remained 
white as opposed to a dark, black reverse for A. unilateralis. 
Balajee et. al. [14] reported that the genus Aspergillus presents 
numerous difficulties for morphological identification. Some 
species exhibit slow sporulation and aberrant conidiophore 
formation, thus requiring DNA sequence-based identification. 
Thus, multiple genes such as found in ribosomal DNA regions 
ITS and the ribosomal subunit D1-D2, as well as structural 
genes of β-tubulin (TUB) and the calmodulin (CAL) genes 
must be used to segregate species within aspergilli. Despite 
the value of gene sequencing, there is no consensus as to the 
genes that can be used to specifically identify the aspergilli to 
species. Growth studies at various temperatures and electron 
microscopic analyses of conidia morphology are still needed to 
fully characterize these fungi. Since our clinical laboratory still 
relies primarily on morphological/physiological identification, 
we could not identify this isolate without the aid of MALDI-
TOF and gene sequencing analysis. Unfortunately, this process 
took 10 weeks to complete. This demonstrates the complexity 
involved in the final diagnosis and subsequent reporting of 
important clinical information related to the treatment of FRS. 
Clinical definitions, manifestations and 
epidemiology overview
The burden of FRS in the United States is not clearly defined. 
However, there is a growing consensus that fungal infections 
worldwide are increasing as certain at-risk populations are 
demonstrating increased survival time [15]. Generally, at 
risk populations for invasive fungal disease are those who 
are immunosuppressed for some reason like age, multiple 
underlying comorbidities, diabetes, malignancy, HIV, or 
receipt of immunosuppressive agents [16]. However, reports 
highlighting outbreaks following natural disasters or antecedent 
trauma in healthy adult populations demonstrate the wide array 
of potentially affected hosts [17]. 
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Figure 3.  Blastomyces dermatitidis.  A. B. dermatitidis in sinus biopsy (ar-
rows), 100X, GMS stain, bar=200µm; B.  B. dermatitidis in sinus biopsy, 
1000X, GMS stain, bar= 20µm; C.  B. dermatitidis in sinus biopsy showing 
broad base budding yeast cells, 1500X, hematoxylin and eosin (H&E) 
stain; D.  B. dermatitidis in sinus biopsy showing thickened cell wall of two 
yeast cells, 2000X, H&E stain. 
Fungi are ubiquitous in the environment and can colonize the 
upper respiratory tract mucosa when fungal spores are inhaled. 
In people with normal immune function, once inhaled the 
fungal growth is kept in check. With impaired host immunity, 
fungi can invade host mucosa and cause invasive disease [18]. 
FRS comprises a spectrum on disease process, which varies 
in clinical presentation, histologic appearance, and biological 
significance. FRS can be acute (aggressive; symptoms <30 
days), subacute (symptoms 30-90 days), and chronic (indolent; 
symptoms >90 days) [19].
Clinically it could be classified as non-invasive or invasive. 
Assessing the viability of the host immune system is central to 
correctly differentiating and managing FRS. Immunity is the key 
predisposing factor for fungal invasion of the sinuses and must 
be considered for all FRS patients. Presumably, fungi are unable 
to penetrate the epithelial layer when the immune system is 
functioning normally. Fungal protease activation of epithelial 
cells can elicit increased cytokine production and the subsequent 
migration of inflammatory cells, including eosinophils which 
migrate through the barrier epithelial cells in response to fungi 
present [20]. Suppression of the immune system, such as from 
diabetes mellitus, chemotherapy, or corticosteroids, creates a 
condition in which fungi can penetrate normal mucosa barriers 
and invade host tissues [21]. Non-invasive rhinosinusitis 
includes: saprophytic fungal infection, fungal ball (FB), and 
allergic fungal rhinosinusitis (AFRS). The invasive forms 
include acute, chronic, and chronic granulomatous. 
Non-invasive rhinosinusitis
AFRS represents a hypersensitive response of a competent 
immune system to fungal elements. The pathogenesis could 
be explained in part through IgE-mediated-(type 1) reaction to 
fungal species trapped in sinonasal mucus. It has been shown 
that fungi induce the production of eosinophil attracting Th2 
cytokines hence, large amount of mucin is produced due allergic 
inflammation [19]. The clinical presentation described includes 
nasal congestion, facial pain and pressure, nasal discharge, and 
diminished olfaction. Epidemiologically patients are younger, 
more likely male, living in warm and humid climates such as 
southern and southeastern United States, India and Middle 
East. Most individuals have a history of atopy including allergic 
rhinitis and/or asthma [19]. 
The FB is described as a dense accumulation of fungal elements 
within a single sinus. The sinus most common affected is the 
maxillary sinus, followed by the sphenoid sinus and unlikely 
with the ethmoid of frontal sinus. These are more common 
in normally functioning immune system, and more common 
in middle-age women. Previously in the literature the FB was 
described as “mycetoma” or “aspergilloma”. FB rarely yield 
positive fungal cultures; however, Aspergillus spp. are the most 
commonly isolated pathogen [19].
Saprophytic fungal infestation describes fungal colonization 
of the sinonasal tract usually after a surgical procedure or a 
traumatic event.  Subsequent inflammation of the sinonasal 
mucosa follows, and infection of the surface mucosa occurs 
without tissue invasion [19]. Nasal crust can become colonized 
by an extensive collection of fungi. This provides an environment 
for fungal replication and nearby mucosa is usually unaffected. 
Hoggard et.al. [20], reported that from one neonatal study 
where nasal mucus specimens were examined, 94% of infants 
yielded positive fungal cultures within the first 4 month of life. 
This led them to suggest that fungi are normal constituents of 
the sinonasal tract. This poses the basis of our case 1 (above) 
which may have initially been colonizing sinonasal flora. The 
genus of Scopulariopsis is one of the most common saprophytic 
filamentous fungi [2]. Invasive disease evolution is very rare; 
when present it’s associated mainly with immunocompromised 
patients.
Categories of Invasive FRS
Acute invasive FRS should be suspected in immunocompromised, 
particularly those on chemotherapy or bone morrow transplant, 
or uncontrolled diabetic patients with acute sinusitis. It 
may also occur in individuals on therapy with chronic oral 
corticosteroids. The presentation of the symptoms occurs in 
less than four weeks. It has indolent clinical presentation like 
nasal congestion, drainage, facial pain/pressure. As the disease 
advances, the patient can develop fever, epistaxis, and extension 
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Figure 4. A. fumigatus grown on SABDX, at 30°C.  A.  14-day old colony; B.  LPCB stain, 400X, bar = 50µm; C.  LPCB stain, 1,000X, 
showing multi-septate, broad conidiophores ending in a central elongated vesicle with an enlarged phialide with cup shaped collaret. 
Secondary conidiophores were often produced from the vesicle; D-F.  LPCB stain, 1,500X, showing multi-septate, broad conidiophores 
ending in a central elongated vesicle with an enlarged phialide having a cup shaped collaret and release of a terminal conidium 
(flat at the base), and primary/secondary metulae terminating in phialides (arrows) with dark collarets and chains of round conidia. 
into to the orbit causing proptosis, ophthalmoplegia, and a 
decreased visual acuity. With eventual dissemination of the 
disease bone erosion may occur. Often diabetics, especially those 
with diabetic ketoacidosis experience invasive fungal infection of 
this type. This is frequently caused by the fungi belonging to the 
order of Zygomycetes, such as Rhizopus, Rhizomucor, Absidia, 
and Mucor. In patients with severe neutropenia, Aspergillus 
species are responsible for up to 80% of infections [22]. Overall, 
the causal agents in invasive fungal sinusitis are the filamentous 
fungi, including Apergillus, Mucor, Rhizozopus, Fusarium, 
Pseudallescheria boydii, and the dematiaceous fungi such as 
Alternaria, Bipolaris, Cladophialophora, and Curvularia spp. 
[23]. 
Clinically invasive FRS is characterized by a painless, necrotic, 
nasal septal ulcer (eschar), sinusitis, and rapid orbital and 
intracranial spread, leading to death. Angioinvasion and 
hematogenous dissemination are common. Microscopic 
evaluation reveals hemorrhage, necrosis, and mixed acute 
and chronic inflammation that may have a granulomatous 
component. Given the urgent nature of acute fulminant 
invasive FRS, intraoperative evaluation of frozen sections may 
be requested, and antibiotic therapy should be initiated before 
culture results are available [24].
Chronic invasive FRS is usually seen among diabetics. The 
definition describes a sinusitis of at least more than twelve 
weeks of duration compatible with radiologic findings and 
histologic evidence of tissue invasion by fungal hyphal forms. 
Histologically it’s characterized by vascular, bone and soft 
tissue invasion; most commonly occurring is Aspergillus 
fumigatus [24]. Fungal-specific cultures can grow a variety of 
species including dematiaceous molds (Bipolaris, Curvularia, 
and Alternaria) [21]. An important key that may play a role in 
paranasal sinus aspergillosis are secretions of a toxic substance 
by fungi that penetrates tissues under appropriate conditions 
and induces tissue necrosis via an immune mechanism. Most 
common symptoms described are diplopia, headache, loss and 
impairment of smelling and nasal stuffiness. Fever is most often 
absent [25].
Granulomatous FRS is a sub-type of chronic invasive FRS. 
The time course is more than twelve weeks. This is described 
more frequently in immunocompetent individuals. The cases 
are more common in countries such as India, Pakistan and 
the Sudan, but there are some cases reported in the United 
States. The presentation is slow progression of the sinusitis with 
headache and unilateral proptosis. Aspergillus fumigatus is the 
responsible agent in most of the cases. The prognosis is better 
than other invasive forms, and patients usually respond to 
debridement, aeration, and antifungal therapy, with recurrence 
being common [24].
Diagnosis of Rhinosinusitis
The diagnosis of invasive FRS is challenging. Often, cultures 
from non-sterile fluid may be difficult to interpret and unable 
to differentiate a pathogen from other flora. Invasive diagnostic 
procedures relying on tissue biopsy or histopathological 
specimens are preferred to make the diagnosis. The timing 
between the diagnosis of FRS and the administration of 
antifungal therapy will often influence the outcome of therapy. 
This phase can be prolonged by diagnostic difficulties, including 
diagnostic markers, such as fungal nucleic acids, antigens, 
antibodies or assays for cell wall components. Detection of 
fungal cell wall components is a rapid and attractive tool 
for diagnosis. Beta-(1,3)-D-glucan (BDG) is one of those 
components and is present in most pathogenic fungi such as 
Candida spp., Fusarium spp., Aspergillus ssp., B. dermititidis, 
and Pneumocystis [26]. Fungi for which BDG is of no value are 
the Zygomycetes and cryptococci which have none to very low 
concentrations of BDG in their cell wall, below that of detection 
in human serum [27].
Galactomannan (GM) as another important cell wall 
component of Aspergillus spp., but it does occur in some fungi 
such as Fusarium spp. During invasive disease, as opposed 
to colonization, the GM is released into the blood-stream 
during intravascular hyphal growth. For this reason, in the 
immunocompromised patient, the serum GM assay has shown 
promise in the diagnosis of invasive aspergillosis. The association 
of elevated serum GM levels are thus indicative (70-95% 
specificity) of invasive aspergillosis. For immunocompromised 
patients with high GM levels, we can tailor the diagnosis to 
aspergillosis when used in combination with elevated C-reactive 
protein and low procalcitonin levels [27]. Low procalcitonin 
often rules-out bacterial infections, but it may still rise in 
some yeast infections, but not so with aspergillosis. However, 
false-positives for GM (45-55% specificity) are well noted, but 
in conjunction with pathology and microbiology results, false-
positives can often be discounted. 
Summary of Histopathologic and 
Microbiologic testing for FRS 
Histopathology
Histopathology of FRS varies depending on whether it is non-
invasive or invasive as discussed above. Montone, et al. [19] 
recently classified the various histopathological criteria of FRS. 
Histologic examination of saprophytic fungal infection reveals 
inflamed and ulcerated sinonasal mucosa with the presence 
of surface fungal organisms without tissue invasion. FB are 
characterized by numerous fungal organisms embedded in 
fibrinous and necrotic exudate with absent to minimal mucosal 
inflammatory reaction [19, 28]. For AFRS, hematoxylin and 
eosin (H&E)-stained histological sections show lamellated 
mucinous material with the presence of eosinophils, eosinophilic 
debris, Charcot-Leyden crystals and rare noninvasive fungal 
hyphae [29]. Schneiderian mucosa reveals thickened basement 
membrane with goblet cell hyperplasia, and numerous 
inflammatory cells with prominent eosinophils. Invasive 
FRS is classified into acute invasive FRS, chronic FRS and 
chronic granulomatous FRS. In acute invasive FRS, histology 
demonstrates rare inflammatory cells, with angioinvasion 
of fungal forms causing thrombosis of the luminal surface, 
often with infarction. H&E stains, Grocott’s methenamine 
silver (GMS) and periodic acid-Schiff (PAS) stains provide 
good contrast of the organisms which allows differentiation 
from other material found in the vascular walls and lumens 
that are often fibrin encompassed (Fig. 5). However, fungal 
morphology is frequently elusive [19]. The histopathology of 
chronic invasive granulomatous FRS is mainly characterized by 
submucosal granulomatous inflammation, a small number of 
fungi, fibrosis, and sometimes reactive epithelial hyperplasia. It 
may also show florid granulomatous inflammation with tissue 
invasion by fungal hyphae. Noncaseating granuloma with giant 
cells and occasional central eosinophilic microgranulomata, as 
well as fibrinoid necrosis, vasculitis, vascular proliferation, and 
perivascular fibrosis are often seen [23]. In contrast, in cases 
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of chronic invasive FRS, histopathology often shows more 
numerous fungal organisms with sparse inflammatory infiltrate 
and occasional angioinvasion and without the presence of 
granulomas [19]. When dematiaceous fungi are involved, a 
lightly stained, H&E stain can be performed; this will show the 
brown colored hyphae of the fungal cell walls (Fig. 5, right) 
when viewed by direct light microscopy. 
Microbiology
Most serious fungal infections of the sinus are due to the 
Zygomycetes, Mucor, Rhizopus, Rhizomucor, Absidia, and 
Cunninghamella but reports exist of sinusitis also caused by 
Apophysomyces, Syncephalstrum, Saksenaea, Cokeromyces, 
Entomopthora, Conidiobolus, and Basidiobolus [30]. 
Aspergillus sp. are the second known leading cause of chronic 
invasive sino-orbital and sino-pulmonary disease as well as 
non-invasive FRS and AFRS [31]. In addition, several hyaline 
molds, dematiaceous molds, Candida, and Basidiomycetes 
may be involved in FRS of immunocompromised patients [32]. 
Therefore, the clinical microbiology of FRS is complex and 
requires lengthy and laborious microbiological techniques to 
recover and identify these microorganisms. 
The diagnostic gold standard is to demonstrate the organism in 
pathological stains followed by isolation of the mold in culture 
of clinical specimens. Realistically this is not always the case. 
In fact, only rarely is a clinical biopsy sent to microbiology for 
recovery of the fungus in culture. Although pathologists can 
accurately recognize fungi in clinical specimens, they are not so 
familiar with morphological characteristics that they can identify 
the organism to fungal family or genus. Although molecular 
technology may change our ability to identify pathogens directly 
from specimens, it is unlikely that this will occur any time soon. 
Therefore, it is extremely important that microbiologists be 
consulted when a specimen is submitted for a diagnosis of FRS. 
The basic microbiology technique is the microscopic 
examination of the fungal stain. Fungal stains commonly 
used in microbiology are potassium hydroxide (10%, KOH), 
Calcofluor white, lacto-phenol-cotton blue (LPCB), LPCB with 
KOH, and to a lesser extent, PAS stain, Fontana-Masson, and 
Giemsa stain. The Gram stain sometimes can reveal fungal 
elements, but often the stain is over or under decolorized which 
makes it difficult to interpret. Culture of the fungus is still the 
primary means of recovery and identification. Polymerase chain 
reaction (PCR), matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI TOF), and DNA 
sequencing techniques have been applied directly to clinical 
samples for the initial identification of fungi, however there is 
still much to be accomplished in these areas before any of these 
will become available as standardized, FDA approved techniques 
in the clinical laboratory. Once the fungal isolate has been 
recovered and grown in pure culture, both MALDI-TOF and DNA 
sequencing can be primarily used for identification. Many clinical 
laboratories now send isolates to reference laboratories for DNA 
sequencing analysis which is extremely accurate, but also costly 
(average of $300/isolate). Both technologies show great promise 
for the future of clinical mycology. 
The outcome of the microbiological workup is dependent upon 
the quality and site and specimen collection. The swab is never 
an optimal sample. Instead, surgically collected tissue including 
exudates, necrotic areas, and tissue biopsies, are optimal. 
Purulent drainage may be submitted to the laboratory, but due to 
its polymicrobic nature, it seldom yields a significant pathogen. 
The transportation of specimens to the laboratory should be 
immediate and at room temperature. If a biopsy specimen is 
sent and zygomycosis is suspected, the laboratory should be 
alerted so that a touch-plate preparation can be performed 
prior to grinding the tissue. The grinding process will often 
destroy hyphae rendering the isolate uncultivable. Microbiology 
laboratories often maintain many different culture media, both 
selective and non-selective for the recovery of fungi [33]. Fungi 
are grown on Sabouraud dextrose agar-Emmon’s modification 
(SABDX), potato dextrose agar, potato flake agar, corn meal agar, 
brain heart infusion agar (BHI) both with and without 5% sheep 
blood and antibiotics, Littman oxgall agar, malt extract agar, 
and Czapek’s agar. Cultures are incubated at 27°C, 30°C, 45°C, 
and >50°C, to achieve optimal growth and culture morphology. 
Increasing the spectrum of media planted and incubation 
temperatures may increase the % recovery and lead to faster 
identifications. Some fungi will develop full growth by 3 days, but 
others may take up to 2 to 4 weeks to fully develop. 
To date, due to cost containment measures, morphological 
growth characteristics are still the most used method of fungal 
identification. Both macroscopic and microscopic observations 
are combined for final identification. Identification involves 
recognition of sexual and asexual structures, color, size, shape, 
ornamentation, septation, yeast forms, conidia production, 
hyphae production, and spore germination. Several new texts are 
available that describe and depict morphological characteristics 
of the various clinically important fungi [33-36]. Morphological 
identification requires extensive training and experience in the 
field of mycology. The fungi are a diverse and complex group of 
microorganisms that may have both sexual and asexual stages of 
growth. For instance, there are 339 known species of Aspergillus 
with nine teleomorph (sexual stage) genera. Recent phylogenic 
studies indicate that this number may soon increase [37]. Of 
these, there are only seven species that are commonly considered 
clinically significant [14]. However, Chen et al., recently reported 
that as many as 48 other uncommon Aspergillus species may be 
pathogenic [38].
Many of the past clinically insignificant fungi have become 
important considerations in FRS for the reasons discussed above. 
The clinical laboratory formerly considered many fungal isolates 
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Figure 5.   Various stains used in Pathology.  Left: H&E stain showing Aspergillus hyphae.  Center:  GMS stain showing a dematiaceous mold 
with septate hyphae.  Right:  H&E lightly stained, showing dematiaceous mold with unstained brown hyphae (arrows).
as normal flora or contaminants and no further work-up was 
done. Now with more immunocompromised patients, clinical 
laboratories are reporting most isolates that occur in culture. 
This has created an enigma in clinical medicine and one must be 
current with the literature to determine if certain fungal isolates 
are pathogenic. The greatest problem herein is that some fungal 
names (genera and species) change with great frequency (every 
fourth year), and a literature search for the isolate reported by the 
laboratory may not yield adequate information to support serious 
consideration. Secondly, the sexual and asexual stages of the fungi 
have different names albeit they are the same microorganism. 
As gene sequencing becomes widely available, this conundrum 
of name changes due to re-classification of genera and species 
based on DNA phylogeny is sure to increase in the upcoming 
years. It is important that anytime an unusual fungus is reported 
on a specimen, that a microbiologist be consulted as to determine 
the clinical significance of the isolate. This includes yeast, yeast-
like, and filamentous fungi. Genetic technology has revealed that 
many fungi that were previously reported to genus and species 
were indeed misidentified, leading mycologists to re-examine 
past cases to determine the prevalence of certain fungi in certain 
disease states [37-43].
Antifungal testing is a delicate, difficult, and often disappointing 
endeavor. Although the Clinical and Laboratory Standards 
Institute (CLSI) has taken great strides to publish both 
techniques and interpretive standards for the susceptibility 
testing of yeasts [44-47] and filamentous fungi [12], only a few 
laboratories offer this technology. The difficulty with minimum 
inhibitory concentration (MIC) interpretations is that there are 
very few outcome studies performed whereby MIC standardized 
susceptibilities were available on fungal isolates. This has limited 
our efforts to establish reliable standard interpretive criteria and 
much is still unresolved toward improvements this area. 
Antibiotic Stewardship of FRS
Treatment of FRS can be very challenging. The patient may 
have colonization or invasive infection with chronic or acute 
FRS and may require aggressive surgical debridement with 
antifungal treatment. Invasive FRS needing treatment is even 
more complex. The host is typically immunocompromised, the 
diagnosis elusive, and the identification prolonged. Because 
of these facts, patients considered having invasive FRS, based 
on risk factors and clinical presentation should be empirically 
started on broad-spectrum intravenous (IV) antifungal 
therapy, while identification is being done. In most cases, IV 
amphotericin B products should be selected. Once identification 
of the isolate is known, or if specific fungi can be ruled out, 
then other antifungal agents could be considered to optimize 
coverage, route of administration, toxicities, efficacy, or cost 
[48-53].
Antifungal agents discussed here target the fungal cell membrane 
(azoles and polyenes) or cell wall (echinocandins) [49]. There 
are other sites targeted by antifungal agents, but these agents are 
typically not used as monotherapy or in treatment of FRS. Table 
1 includes commonly used systemic antifungal agents in the 
hospital or outpatient setting. Some of these antifungal classes 
share similar side effects or considerations, whereas others have 
their own specific concerns. For example, all triazoles can affect 
QTc measurements (all prolong, except isavuconazole, which 
shortens) and have many drug-drug interactions. Whereas, 
caution must be displayed when deciphering itraconazole 
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Table 1. Common Antifungal Agents and Considerations when Treating Systemic Infections [49, 51-55]
Antifungal 
Agent
Class Mechanism of 
Action




Fluconazole Triazole Ergosterol 
inhibitor
800 mg times 1 dose, then 
400 mg daily
IV/Oral Hepatic effects, QTc prolongation, skin 
reactions, drug-drug interactions
Isavuconazole Triazole 372 mg (isavuconazole 200 
mg) every 8 hours for 6 
doses, then 372 mg (200 mg 
isavuconazole) daily
IV/Oral Hepatic effects, GI effects, QTc 
narrowing, CNS effects, skin reactions, 
drug-drug interactions, high cost (no 
generic available), risk of dosing errors 
due to prodrug dosing
Itraconazole Triazole 200 mg 3 times daily for 
3 days, then 200 mg twice 
daily
Oral Hepatic effects, cardiomyopathy, GI 
effects, QTc prolongation, skin reac-
tions, type of formulation, drug-drug 
interaction, patient tolerability, high 
cost dependent on product
Posaconazole Triazole Suspension: 200 mg 3 times 
daily with high fat meal 
preferred
IV/Delayed Release oral: 
300 mg twice daily, then 300 
mg daily
IV/Oral Hepatic effects, QTc prolongation, CNS 
effects, GI effects, skin reactions, type 
of formulation, absorption, potential 
for drug monitoring depending on 
formulation, patient tolerability, avoid 
IV use in renal insufficiency, high cost 
(no generic available)
Voriconazole Triazole 6 mg/kg every 12 hours for 
2 doses then 4 mg/kg every 
12 hours
IV/Oral Hepatic effects, CNS effects, visual 
disturbances, QTc prolongation, skin 
reactions, drug-drug interactions, 
avoid IV use in renal insufficiency
Anidulafungin Echinocandin β-1,3-D-glucan 
synthesis 
inhibitor
200 mg once, then 100 mg 
daily
IV Hepatic effects, cardiovascular effects, 
insomnia, infusion reactions, only 
available IV, high cost
Caspofungin Echinocandin 70 mg once, then 50 mg 
daily
IV Hepatic effects, cardiovascular effects, 
CNS effects, localized phlebitis, infu-
sion reactions, only available IV, high 
cost (no generic available)
Micafungin Echinocandin 100-150 mg daily IV Hepatic effects, cardiovascular effects, 
CNS effects, GI effects, hemolytic ane-
mia/hemoglobinuria, only available IV, 





3-5 mg/kg/day IV Hepatic effects, nephrotoxicity, electro-
lyte abnormalities infusion reactions, 
anemia, only available IV, patient 
tolerability, high cost (no generic 
available)
GI=Gastrointestinal, CNS=Central Nervous System
capsules or tablets versus the suspension, since gastric acid 
affects the absorption (capsules/tablets should be taken with 
food, but the suspension is preferred and should be taken on an 
empty stomach) [49, 50].
Good antifungal stewardship practices should be utilized when 
possible. Once the fungus has been identified, the antifungal 
may be narrowed. However, many considerations need to 
be made and a multi-disciplinary approach should be used 
for medication transitions. Susceptibilities should always be 
checked since resistance by many fungi has been observed [49, 
50, 56]. A clinical pharmacist, specifically trained in infectious 
disease if available, can assist the team in selecting the best 
option based on drug-drug interactions, common side effects or 
toxicities, absorption concerns, dosing (using pharmacokinetic 
and pharmacodynamics parameters), cost, and potentially 
therapeutic antifungal monitoring goals. Good antifungal 
stewardship with a multi-disciplinary approach is important 
because it helps ensure an optimized antifungal regimen that is 
both safe and efficacious.
Summary
We presented four human case reports of fungi that cause 
FRS. All four cases originated at our Veterans’ hospital within 
a two-year period. The diagnosis and therapy in all four 
cases required a full spectrum of professional contributions: 
Infectious Disease Specialists, Pathologists, Microbiologist, and 
Clinical Pharmacists. It is important for ENT specialists and 
other disciplines of medicine to recognize that the fungi of FRS 
are complex microorganisms that encompass a wide variety of 
species (pathogenic and formerly non-pathogenic), and they are 
very difficult to recognize and identify. The current technology 
to identify fungi is lengthy, and optimum patient therapy is 
often delayed. Likewise, the host range of immunocompetent 
and immunocompromised individuals further complicates the 
clinical presentation of their various disease states. Antifungal 
therapy for FRS is vague in the literature, thus antimicrobial 
stewardship is important for patient care. The toxicity of 
antifungals is of significant concern and requires the skills of 
both Infectious Disease specialists and Pharmacists to establish 
the best dosing regimen. We briefly reviewed and summarized 
the contributions of many other authors to show the extensive 
amount of work already done in this area. There is yet much to 
be accomplished before FRS can be fully appreciated as a cause 
of significant morbidity and mortality. We attribute our success 
in this area to the willingness of our professional staff to work 
closely together and overcome the many challenges that are 
faced when a patient presents with FRS. 
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